FDA Blasts Zhejiang Huahai for Failing to Investigate Contamination Fully

Drug Industry Daily
The FDA issued a warning letter to Chinese API maker Zhejiang Huahai, the company implicated in a global recall of contaminated valsartan, for failing to adequately investigate the root cause of the NDMA contamination at its Linhai, Taizhou Zhejiang facility.

To View This Article:


Subscribe To Drug Industry Daily